I don’t expect any changes in pps until FDA approval. Tomorrow won’t change anything. GLTA

Titan is sitting on a gem. That said, pps won’t appreciate until the company starts to generate revenue. Expect 0.20-.30 cent range for remainder of this year. This will get one nice bump at FDA approval (not submission) before the real fun. As far as buyouts, I don’t see it happening considering it hasn’t transpired by now. My logic, it’s Titans weakest moment and should’ve been gobbled up when it was at 10 cents a share. GLTA

Titan is sitting on a gem. That said, pps won’t appreciate until the company starts to generate revenue. Expect 0.20-.30 cent range for remainder of this year. This will get one nice bump at FDA approval (not submission) before the real fun. As far as buyouts, I don’t see it happening considering it hasn’t transpired by now. My logic, it’s Titans weakest moment and should’ve been gobbled up when it was at 10 cents a share. GLTA

Based on what facts?

A publicly funded company doesn’t lose money everyday. There are no loans with Titan and their value is fair with all the patents they received. This company will either go the distance, partner up or get bought out. The question is when and how much? The robots value increases everyday as it gets exposed to a wide variety of conferences, but time is extra slow in the medical field.

Sorry, I don’t quite follow what you’re saying.

What’s a good number of shares to have in a stock like this? I know more the better but just trying to exercise some caution. I agree that this is game changing technology.

My fear is that the design freeze won’t happen til next year as planned by design. This gives to much time for the stock to dilute. I’ve averaged my shares at 36 cents and worried the pop from the design freeze won’t over come this. Another point to make is why reverse split? If the company and shareholders are so confident in the device, why not keep the plan of action, wait for the share price to reach nasdaq requirements and then up list? The company will generate plenty of revenue to buy back and consolidate its share count if the device is a true competitor against DiVinci. - my opinion / speculation.

While I’m glad there is excitement on this board, why do I feel like I’m the only one who feels the stock won’t appreciate until FDA approval is achieved and revenue is produced through sales?!? I feel like I’m missing something here...

If this were to happen, and our shares get consolidated with Intuitive, what does that do the value of the share? Would everyone go positive in this scenario if the break even was PPS, say for instance, 50 cents?

I’m sorry to all on the board, been on call for a week and haven’t kept up. What’s all the excitement for? Did something big happen?

Sorry, what is this hearing? What does it means and significance? Thank you.

Translation?

Is the Bid this morning correct?

Question. why does everyone presume a partnership will send the stock flying? Their product has not been submitted or approved by FDA/CE. Even after approval, they need sales. Only then will this stock lift off. And while it’s been a long road, I still believe that will be the case.

I agree with your statement as well. The negative criticism is silly without having evidence. It’s no surprise, to me, the offering went well. Panic when you need to panic... and thanks to which ever moderator deleted my message ??

How does a company without loans go bankrupt? Public funding...

The company behaves as if it wants to go the distance the whole way. Diluting shares and then consolidating based on the pps at the time of uplifting. Everyone also forgets they can buy back shares presuming they make a killing in their first year of sales. Remember, they are going to try and over price SPORT originally (but still remain far more affordable then Di Vinci) at the start of the whole process. First thing is first, get to and pass FDA. Partner up of ya can’t get the remaining funds, which at this pace, doesn’t seem necessary.

Long time follower. First time post.

This is a very exciting time for this company. They have achieved recognition in three largely named institutions that have voiced high regards towards their single incision robotics device. Everyone should know that the company’s goal is to get this thing to commercialization and to have the funding to back it up.

A smart investor knows that a company like this is very risky at start up. They’re always setbacks however in this scenario they are close to the finish line. Their plan is very simple, get the required funding to commercialization. The way I’m interpreting all this, these guys do not want to partner to tap into an 18 billion dollar market when they can exercise all opportunities to go the distance themselves. That said they understand the possibility that it may not happen. But the more they increase their funding and timeframe to FDA submission/approval and commercialization, their value increases substantially. If I was CEO, I wouldn’t partner / accept a low ball by out, especially knowing the technology I have. I would make every effort to go the distance or achieve the maximum value of the company before partnering/buy out. Their current race will be a fart in the wind to their current number of outstanding shares as is. There’s no need to panic over this. At the end this looks like it will make a decent amount in the long run (look at ISURG).

By the way, you only lose money when you sell a stock in the red. If you’re inpatient and not willing to take the risk this is not a company for you. You don’t make money off these kinds of start ups right out of the bag. Especially when they do not have a product to sell or revenue to generate. When this company start selling it’s robot that’s when we will see a nice swing upward.